Scotiabank analyst Nicholas Yulico upgraded Healthpeak to Outperform from Sector Perform with a price target of $23, up from $20. While the firm still believes the overall lab space market has supply/demand imbalances to resolve, it thinks the stock’s current discounted valuation doesn’t give credit for the company’s attractive portfolio, the analyst tells investors. In addition, recent channel checks in Boston and South San Francisco, two of the company’s core lab space markets, point to a pickup in market leasing demand at the same time that Healthcare M&A has picked up, the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PEAK:
- Healthpeak enters into $236M JV with Breakthrough Properties
- Healthpeak price target raised to $24 from $22 at Evercore ISI
- Physicians Realty Trust downgraded to Sector Weight from Overweight at KeyBanc
- Best Stock to Buy Today, 1/2/2024, According to Top Analysts
- Healthpeak receives entitlements for extra 1.3M square feet at Vantage Campus